Barclays Maintains Overweight on Legend Biotech, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $92 to $93.
October 18, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Legend Biotech and raises the price target from $92 to $93, indicating a positive outlook for the company.
The raised price target by Barclays indicates their belief in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100